A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-511881-35-00

Acronym

INCB 54707-306

Enrollment

170

Registered

2024-12-03

Start date

2024-12-17

Completion date

Unknown

Last updated

2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prurigo Nodularis

Brief summary

Proportion of participants achieving Itch NRS4 (≥ 4-point improvement [reduction] in Itch NRS score from baseline) and IGA-CPG-S-TS (IGA CPG-S score of 0 or 1 with a ≥ 2-grade improvement from baseline) at Week 24

Detailed description

Proportion of participants achieving Itch NRS4 at Week 24, Proportion of participants achieving IGA CPG S-TS at Week 24, Proportion of participants achieving Itch NRS4 at Week 4

Interventions

DRUGPovorcitinib

DRUGPlacebo to Povorcitinib

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Proportion of participants achieving Itch NRS4 (≥ 4-point improvement [reduction] in Itch NRS score from baseline) and IGA-CPG-S-TS (IGA CPG-S score of 0 or 1 with a ≥ 2-grade improvement from baseline) at Week 24	—

Secondary

Measure	Time frame
Proportion of participants achieving Itch NRS4 at Week 24, Proportion of participants achieving IGA CPG S-TS at Week 24, Proportion of participants achieving Itch NRS4 at Week 4	—

Countries

Belgium, Czechia, Germany, Poland, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026